Trial · NCT02711137
Participant flow45
How many started, completed or left each group, period by period.
1 to 20 of 45
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part1/Treatment Group A : 8mg QD INCB057643 | 4 | |
| Overall Study | STARTED | Part1/Treatment Group A : 12mg QD INCB057643 | 5 | |
| Overall Study | STARTED | Part1/Treatment Group A : 16mg QD INCB057643 | 8 | |
| Overall Study | STARTED | Part1/Treatment Group B : 8mg QD INCB057643 | 7 | |
| Overall Study | STARTED | Part1/Treatment Group B : 12mg QD INCB057643 | 5 | |
| Overall Study | STARTED | Part1/Treatment Group C : 8mg QD INCB057643 | 1 | |
| Overall Study | STARTED | Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort | 86 | |
| Overall Study | STARTED | Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort | 5 | |
| Overall Study | STARTED | Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg | 1 | |
| Overall Study | STARTED | Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg | 2 | |
| Overall Study | STARTED | Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg | 4 | |
| Overall Study | STARTED | Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni | 3 | |
| Overall Study | STARTED | Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg | 1 | |
| Overall Study | STARTED | Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg | 2 | |
| Overall Study | STARTED | Enrolled But Not Dosed | 3 | |
| Overall Study | COMPLETED | Part1/Treatment Group A : 8mg QD INCB057643 | 0 | |
| Overall Study | COMPLETED | Part1/Treatment Group A : 12mg QD INCB057643 | 0 | |
| Overall Study | COMPLETED | Part1/Treatment Group A : 16mg QD INCB057643 | 0 | |
| Overall Study | COMPLETED | Part1/Treatment Group B : 8mg QD INCB057643 | 0 | |
| Overall Study | COMPLETED | Part1/Treatment Group B : 12mg QD INCB057643 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02711137/flow